$BIOLQ
BIOLASE, INC

2014 Q4 Form 10-K Financial Statement

#000156459015001392 Filed on March 06, 2015

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014
Revenue $13.24M $12.71M $47.66M
YoY Change -13.12% 2.95% -15.55%
Cost Of Revenue $8.230M $7.400M $29.48M
YoY Change -8.86% -14.05% -15.52%
Gross Profit $5.010M $5.320M $18.17M
YoY Change -19.45% 42.25% -15.6%
Gross Profit Margin 37.84% 41.84% 38.13%
Selling, General & Admin $7.480M $6.360M $31.23M
YoY Change 3.89% -0.16% 11.3%
% of Gross Profit 149.3% 119.55% 171.85%
Research & Development $1.350M $1.276M $4.577M
YoY Change 29.81% 30.2% 13.6%
% of Gross Profit 26.95% 23.98% 25.19%
Depreciation & Amortization $170.0K $160.0K $696.0K
YoY Change 6.25% 14.29% 15.81%
% of Gross Profit 3.39% 3.01% 3.83%
Operating Expenses $8.830M $8.688M $36.11M
YoY Change 7.16% 18.2% 11.03%
Operating Profit -$3.820M -$3.368M -$17.94M
YoY Change 89.11% -6.7% 63.16%
Interest Expense -$260.0K -$170.0K -$458.0K
YoY Change 36.84% 0.0% -23.67%
% of Operating Profit
Other Income/Expense, Net -$172.0K -$873.0K
YoY Change 3.61% 34.31%
Pretax Income -$4.070M -$3.467M -$18.81M
YoY Change 83.33% -13.91% 61.55%
Income Tax $30.00K $28.00K $112.0K
% Of Pretax Income
Net Earnings -$4.110M -$3.495M -$18.93M
YoY Change 84.3% -13.68% 64.83%
Net Earnings / Revenue -31.04% -27.49% -39.71%
Basic Earnings Per Share -$0.08 -$0.45
Diluted Earnings Per Share -$392.2K -$0.08 -$0.45
COMMON SHARES
Basic Shares Outstanding 42.40M 42.23M
Diluted Shares Outstanding 42.40M 42.23M

Balance Sheet

Concept 2014 Q4 2014 Q3 2014
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.56M $2.760M $31.56M
YoY Change 2091.67% -33.49% 2091.67%
Cash & Equivalents $31.56M $2.760M $31.56M
Short-Term Investments
Other Short-Term Assets $1.730M $1.290M $1.730M
YoY Change -9.42% 21.7% -9.42%
Inventory $12.51M $11.80M $12.51M
Prepaid Expenses
Receivables $9.004M $9.260M $8.890M
Other Receivables $29.00K $0.00 $110.0K
Total Short-Term Assets $54.80M $25.11M $54.80M
YoY Change 111.95% -9.55% 111.99%
LONG-TERM ASSETS
Property, Plant & Equipment $1.295M $1.470M $1.300M
YoY Change -29.08% -14.04% -28.96%
Goodwill $2.926M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K $270.0K $270.0K
YoY Change 8.43% 3.85% 8.0%
Total Long-Term Assets $4.605M $4.790M $4.600M
YoY Change -11.17% -6.08% -11.37%
TOTAL ASSETS
Total Short-Term Assets $54.80M $25.11M $54.80M
Total Long-Term Assets $4.605M $4.790M $4.600M
Total Assets $59.40M $29.90M $59.40M
YoY Change 91.39% -9.01% 91.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.360M $9.535M $8.360M
YoY Change -2.34% 1.98% -2.34%
Accrued Expenses $4.870M $5.697M $4.870M
YoY Change -2.54% 43.5% 12.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.15M $17.77M $16.15M
YoY Change -26.39% -21.77% -26.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $520.0K $370.0K $520.0K
YoY Change 1133.33%
Total Long-Term Liabilities $520.0K $370.0K $520.0K
YoY Change 1133.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.15M $17.77M $16.15M
Total Long-Term Liabilities $520.0K $370.0K $520.0K
Total Liabilities $17.35M $18.80M $17.35M
YoY Change -23.08% -19.52% -23.09%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $185.2M
YoY Change 24.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $1.964M
Shareholders Equity $42.06M $11.10M $42.06M
YoY Change
Total Liabilities & Shareholders Equity $59.40M $29.90M $59.40M
YoY Change 91.38% -9.01% 91.37%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014
OPERATING ACTIVITIES
Net Income -$4.110M -$3.495M -$18.93M
YoY Change 84.3% -13.68% 64.83%
Depreciation, Depletion And Amortization $170.0K $160.0K $696.0K
YoY Change 6.25% 14.29% 15.81%
Cash From Operating Activities -$5.930M -$7.370M -$16.20M
YoY Change 168.33% 270.35% 74.27%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$70.00K $198.0K
YoY Change -95.45% -46.15% -70.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$10.00K -$70.00K -$200.0K
YoY Change -95.45% -46.15% -70.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $34.80M $11.50M $51.12M
YoY Change 882.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.82M 8.250M 46.75M
YoY Change -11332.26% 100.73% 428.43%
NET CHANGE
Cash From Operating Activities -5.930M -7.370M -16.20M
Cash From Investing Activities -10.00K -70.00K -200.0K
Cash From Financing Activities 34.82M 8.250M 46.75M
Net Change In Cash 28.88M 810.0K 30.35M
YoY Change -1154.01% -59.3% -2776.37%
FREE CASH FLOW
Cash From Operating Activities -$5.930M -$7.370M -$16.20M
Capital Expenditures -$10.00K -$70.00K $198.0K
Free Cash Flow -$5.920M -$7.300M -$16.40M
YoY Change 197.49% 292.47% 64.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
183000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
250000
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42232000
CY2012 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
235000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
142000
CY2013Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4633000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4997000
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
617000
CY2014Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
42056000
CY2013Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
24880000
CY2014 biol Excise Tax
ExciseTax
307000
CY2014 us-gaap Operating Expenses
OperatingExpenses
36113000
CY2014 us-gaap Interest And Debt Expense
InterestAndDebtExpense
458000
CY2013 us-gaap Interest And Debt Expense
InterestAndDebtExpense
600000
CY2012 us-gaap Interest And Debt Expense
InterestAndDebtExpense
239000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-873000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-18814000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11646000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2945000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
112000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
111000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-18926000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-283000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19209000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32768000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42232000
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32768000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
12569000
CY2011Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
455000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1600000
CY2012 biol Adjustments To Additional Paid In Capital Non Employee Equity Instruments
AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments
23000
CY2012 biol Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
6000
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
709000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1609000
CY2013 biol Adjustments To Additional Paid In Capital Non Employee Equity Instruments
AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments
106000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3464000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21939000
CY2014Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
519000
CY2014 biol Products And Services Revenue
ProductsAndServicesRevenue
47511000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
270000
CY2014Q4 us-gaap Assets
Assets
59403000
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
47656000
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
56430000
CY2013 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18682000
CY2013 us-gaap Gross Profit
GrossProfit
21530000
CY2013 us-gaap Cost Of Revenue
CostOfRevenue
34900000
CY2012 us-gaap Cost Of Revenue
CostOfRevenue
30878000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
185231000
CY2012 us-gaap Gross Profit
GrossProfit
26478000
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-415000
CY2013 us-gaap Operating Expenses
OperatingExpenses
32526000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-17941000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-10996000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148866000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2013Q4 us-gaap Liabilities
Liabilities
22557000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-274000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123750000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1233000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
114000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8560000
CY2013Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
285000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1000
CY2013 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-50000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-2531000
CY2013 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
244000
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16375000
CY2012 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
165000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14854000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8075000
CY2014 us-gaap Gross Profit
GrossProfit
18172000
CY2014 us-gaap Cost Of Revenue
CostOfRevenue
29484000
CY2014 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
145000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4577000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4029000
CY2012 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16250000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9377000
CY2013 biol Products And Services Revenue
ProductsAndServicesRevenue
56186000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4684000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-414000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-11482000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11436000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-3056000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
40000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3016000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-650000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-164000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
46000
CY2012 us-gaap Operating Expenses
OperatingExpenses
29009000
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
57356000
CY2013 biol Excise Tax
ExciseTax
438000
CY2012 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-175000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
61000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
60000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-30000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3222000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
451000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
198000
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32162000
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32162000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
11794000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
25000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-27000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
52000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-134000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
60000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
72000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
310000
CY2014 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
1964000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
123000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
51118000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
696000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
601000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
250000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5169000
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
280000
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
513000
CY2014 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-9000
CY2012 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-15000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1295000
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
291000
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
241000
CY2014 us-gaap Inventory Write Down
InventoryWriteDown
585000
CY2013 us-gaap Inventory Write Down
InventoryWriteDown
1132000
CY2012 us-gaap Inventory Write Down
InventoryWriteDown
330000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
200000
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
179000
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43000
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
128000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
197000
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
91000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1233000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1609000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1600000
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
106000
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
23000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-123000
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-250000
CY2012 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-250000
CY2013 us-gaap Interest Expense Debt
InterestExpenseDebt
27000
CY2012 us-gaap Interest Expense Debt
InterestExpenseDebt
19000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-826000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-264000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1715000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1436000
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
160000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
21000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-56000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-450000
CY2014 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-174000
CY2013 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-297000
CY2012 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
417000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-999000
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-347000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-971000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
236000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1068000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16201000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9296000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1664000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
675000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
808000
CY2014 biol Proceeds From Disposal Of Long Lived Assets
ProceedsFromDisposalOfLongLivedAssets
1000
CY2012 biol Proceeds From Disposal Of Long Lived Assets
ProceedsFromDisposalOfLongLivedAssets
124000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
183000
CY2013 us-gaap Depreciation
Depreciation
484000
CY2012 us-gaap Depreciation
Depreciation
377000
CY2013Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
428000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1581000
CY2014Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
139000
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-197000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-685000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-698000
CY2014 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
16875000
CY2013 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
35100000
CY2012 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
16600000
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
21508000
CY2013 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
32104000
CY2012 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
14963000
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
45000
CY2013 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
57000
CY2012 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
304000
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51118000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5201000
CY2012 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
235000
CY2014 biol Proceeds From Collection Of Receivables And Exercise Of Stock Options
ProceedsFromCollectionOfReceivablesAndExerciseOfStockOptions
312000
CY2013 biol Proceeds From Collection Of Receivables And Exercise Of Stock Options
ProceedsFromCollectionOfReceivablesAndExerciseOfStockOptions
707000
CY2012 biol Proceeds From Collection Of Receivables And Exercise Of Stock Options
ProceedsFromCollectionOfReceivablesAndExerciseOfStockOptions
455000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
46752000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8847000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1559000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-234000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
31000
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
39000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
30120000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1103000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-764000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2543000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3307000
CY2014 us-gaap Interest Paid
InterestPaid
148000
CY2013 us-gaap Interest Paid
InterestPaid
220000
CY2012 us-gaap Interest Paid
InterestPaid
88000
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
52000
CY2013 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
47000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
62000
CY2012 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
200000
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U. S. GAAP&#8221;) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals for multiple element arrangements, effects of stock-based compensation and warrants, contingent liabilities and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </p></div>
CY2014Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1119000
CY2014Q4 us-gaap Land
Land
176000
CY2014Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2400000
CY2014Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
6788000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5669000
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk, interest rate risk and foreign currency exchange rate risk </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However it has required certain distributors to make prepayments for significant purchases of products. For the years ended December&#160;31, 2014, 2013, and 2012, worldwide sales to the Company&#8217;s largest distributor, Henry Schein, Inc. (&#8220;HSIC&#8221;), accounted for approximately 6%, 5%, and 3%, respectively, of our net sales. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, including the facilities, consulting services and employee-related costs. Through the year ended December 31, 2014, the Company has not entered into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the United States. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding balances on the Company&#8217;s lines of credit expose it to variable interest rate risks associated with fluctuations in the daily prime rate and LIBOR rate. Under the Company&#8217;s current policies, it does not use interest rate derivative instruments to manage exposure to interest rate changes. Increases in the daily prime rate or LIBOR rate would increase the costs of borrowing and accordingly, the interest expense the Company must pay. However, as of December 31, 2014, the Company did not have a line of credit facility.</p></div>
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11500000
CY2014Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34800000
CY2014Q4 biol Working Capital
WorkingCapital
38600000
CY2014Q3 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2900000
CY2014Q4 biol Proceeds From Sale Of Common Stock Gross
ProceedsFromSaleOfCommonStockGross
35000000
CY2014Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14162873
CY2014Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.39
CY2014Q4 biol Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
9205862
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.00
CY2014Q4 biol Term Of Warrant
TermOfWarrant
P3Y
CY2014Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
235000
CY2014Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6250000
CY2014Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.92
CY2014Q3 biol Proceeds From Sale Of Common Stock Gross
ProceedsFromSaleOfCommonStockGross
12000000
CY2014Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
462000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1945525
CY2014Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.57
CY2014Q1 biol Proceeds From Sale Of Common Stock Gross
ProceedsFromSaleOfCommonStockGross
5000000
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
188000
CY2014 us-gaap Depreciation
Depreciation
627000
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
952000
CY2013Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1823000
CY2014 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
110000
CY2013 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
110000
CY2014Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1500000
CY2013Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1642000
CY2013Q4 biol Percentage Of Fair Value Of Exchange To Recognize Revenue
PercentageOfFairValueOfExchangeToRecognizeRevenue
0.25
CY2013Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1096000
CY2012Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1699000
CY2011Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2218000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2617000
CY2014Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2014 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1214000
CY2013 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
475000
CY2012 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1705000
CY2014 us-gaap Product Warranty Expense
ProductWarrantyExpense
861000
CY2013 us-gaap Product Warranty Expense
ProductWarrantyExpense
1078000
CY2012 us-gaap Product Warranty Expense
ProductWarrantyExpense
2224000
CY2014Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1449000
CY2013Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
0
CY2012Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
0
CY2014Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
930000
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1096000
CY2012Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1699000
CY2014 us-gaap Advertising Expense
AdvertisingExpense
543000
CY2013 us-gaap Advertising Expense
AdvertisingExpense
1500000
CY2012 us-gaap Advertising Expense
AdvertisingExpense
907000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1233000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1609000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1600000
CY2014 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.03
CY2013 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.05
CY2012 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.05
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1400000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P10M24D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y9M29D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y7M24D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y8M12D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.94
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.97
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0077
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10094000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6039000
CY2014Q4 biol Trade Accounts Receivables
TradeAccountsReceivables
8887000
CY2013Q4 biol Trade Accounts Receivables
TradeAccountsReceivables
10960000
CY2014Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
88000
CY2013Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
82000
CY2014Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
29000
CY2013Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
85000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1700000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
573000
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2800000
CY2013Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8598000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6971000
CY2013Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1627000
CY2013Q4 us-gaap Land
Land
199000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1905000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1898000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
52000
CY2013Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
338000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
911000
CY2014Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
450000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
326000
CY2014Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1542000
CY2013Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1642000
CY2014Q4 us-gaap Deferred Revenue
DeferredRevenue
2494000
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
3465000
CY2013Q4 us-gaap Extended Product Warranty Accrual Noncurrent
ExtendedProductWarrantyAccrualNoncurrent
1000
CY2014Q3 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
708000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
117000
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
136000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
62000
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2014 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
Indefinite life
CY2013Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2014 biol Number Revolving Credit Facility Agreements
NumberRevolvingCreditFacilityAgreements
2
CY2014Q1 biol Amendments And Administrative Fees
AmendmentsAndAdministrativeFees
10000
CY2014Q2 biol Amendments And Administrative Fees
AmendmentsAndAdministrativeFees
10000
CY2014Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5000000
CY2014Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
4000000
CY2014 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-05-01
CY2014Q2 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-06-01
CY2014Q2 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-08-01
CY2014Q2 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-08-01
CY2014Q2 biol Line Of Credit Non Compliance Payments
LineOfCreditNonCompliancePayments
10000
CY2014Q2 biol Line Of Credit Non Compliance Payments
LineOfCreditNonCompliancePayments
15000
CY2014Q2 biol Line Of Credit Non Compliance Payments
LineOfCreditNonCompliancePayments
10000
CY2014Q2 us-gaap Debt Instrument Interest Rate Increase Decrease
DebtInstrumentInterestRateIncreaseDecrease
0.0050
CY2012Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
8000000
CY2013Q4 us-gaap Line Of Credit
LineOfCredit
4600000
CY2014Q4 biol Prime Floor
PrimeFloor
0.0250
CY2013Q4 biol Prime Floor
PrimeFloor
0.0250
CY2014 us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.0025
CY2013 us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.0025
CY2014 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
457000
CY2013 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
599000
CY2014Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0
CY2013Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
20000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2014 biol Additional Commitment Fees And Legal Costs Incurred
AdditionalCommitmentFeesAndLegalCostsIncurred
55000
CY2013 biol Additional Commitment Fees And Legal Costs Incurred
AdditionalCommitmentFeesAndLegalCostsIncurred
67000
CY2013Q4 biol Financed Insurance Premium Payable
FinancedInsurancePremiumPayable
0
CY2012Q4 biol Financed Insurance Premium Payable
FinancedInsurancePremiumPayable
197000
CY2014 us-gaap Short Term Debt Description
ShortTermDebtDescription
Nine
CY2014 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
3000
CY2013 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
5000
CY2012 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
5000
CY2013Q4 biol Financed Insurance Premium Finance Charge
FinancedInsurancePremiumFinanceCharge
0.029
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-138000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
27000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
31000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2686000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
18000
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
32000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
50000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
57000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-118000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
12000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
16000
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-8000
CY2013 biol Current Federal Tax Expense Benefit Gross
CurrentFederalTaxExpenseBenefitGross
138000
CY2013 biol Income Tax Reconciliation Tax Credits Alternative Minimum Tax And Research And Development
IncomeTaxReconciliationTaxCreditsAlternativeMinimumTaxAndResearchAndDevelopment
107000
CY2013 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
245000
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.374
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.270
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.130
CY2013 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.009
CY2012 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.162
CY2012 biol Effective Income Tax Rate Reconciliation Federal Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationFederalNetOperatingLossExpiration
0.282
CY2013 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
0.031
CY2012 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
0.037
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.033
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.042
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.019
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.021
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2013 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.002
CY2012 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.006
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.010
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.016
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.061
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.023
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.142
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.008
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.003
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.005
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.006
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.014
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
CY2014Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
202000
CY2013Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
283000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1871000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1702000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2911000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2565000
CY2014Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
8000
CY2013Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
7000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2200000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1583000
CY2014Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
1225000
CY2013Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
871000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
280000
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
376000
CY2014Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
222000
CY2013Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
109000
CY2014Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
136000
CY2013Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
142000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33140000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28058000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42203000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
138000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35704000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42069000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35566000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
134000
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
752000
CY2013Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
696000
CY2014Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
59000
CY2013Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
59000
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
811000
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
755000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
677000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
617000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
93200000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
63900000
CY2014 biol Unrecognized Tax Benefits That Would Impact Additional Paid In Capital
UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital
6900000
CY2013 biol Unrecognized Tax Benefits That Would Impact Additional Paid In Capital
UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital
7000000
CY2014Q4 biol Unrecognized Tax Benefits Impact Additional Paid In Capital If Realized
UnrecognizedTaxBenefitsImpactAdditionalPaidInCapitalIfRealized
2600000
CY2013Q4 biol Unrecognized Tax Benefits Impact Additional Paid In Capital If Realized
UnrecognizedTaxBenefitsImpactAdditionalPaidInCapitalIfRealized
2700000
CY2013Q4 biol Valuation Allowance State Dta
ValuationAllowanceStateDta
1.00
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2014Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2006Q1 biol Lease Term
LeaseTerm
P5Y
CY2006Q1 biol Lease Facility Area
LeaseFacilityArea
57000
CY2006Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
38692
CY2009Q3 biol Period For Extended Lease
PeriodForExtendedLease
2015-04-20
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
597000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
306000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
131000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1034000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1100000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
789000
CY2014Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
14100000
CY2013 us-gaap Legal Fees
LegalFees
250000
CY2014 us-gaap Legal Fees
LegalFees
0
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
1963500
CY2013Q3 biol Maximum Stock Offering Price
MaximumStockOfferingPrice
5000000
CY2013Q4 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2013-12-31
CY2013Q3 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2013-09-30
CY2013Q2 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2013-06-30
CY2013Q1 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2013-03-31
CY2013Q4 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2013-12-16
CY2013Q3 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2013-08-30
CY2013Q2 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2013-06-14
CY2013Q1 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2013-03-15
CY2014Q1 biol Special Stock Dividends Intended
SpecialStockDividendsIntended
0.02
CY2014Q1 biol Percentage Of Stock Dividends Payable
PercentageOfStockDividendsPayable
0.0050
CY2014Q1 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2014-03-14
CY2014 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
0
CY2011Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
2000000
CY2012 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
1.73
CY2013Q1 biol Required Minimum Share Price Reached To Exercise Warrants
RequiredMinimumSharePriceReachedToExerciseWarrants
6.00
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3858000
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
214000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
966000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3860000
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
343000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
765000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4441000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
153000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1422000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3475000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2627000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
185000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.75
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.12
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.63
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.48
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.07
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.23
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.51
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.03
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.50
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.03
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.00
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
10.04
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y11M19D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y5M16D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1076000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
975000
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
3475000
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.03
CY2014 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P2Y11M19D
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2627000
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.00
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
310000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
707000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
455000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
108000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
860000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.61
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.82
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.39
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1208000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1544000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1737000
CY2014 biol Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedDescription
One-sixth of the stock options and one-sixth of the RSUs vested immediately, with the remaining five-sixths vesting ratably on a monthly basis over the twelve-month period ending on July 13, 2015.
CY2014 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
Less than 10%
CY2013 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
Less than 10%
CY2014 biol Entity Wide Accounts Receivable Major Customer Number
EntityWideAccountsReceivableMajorCustomerNumber
0
CY2013 biol Entity Wide Accounts Receivable Major Customer Number
EntityWideAccountsReceivableMajorCustomerNumber
0

Files In Submission

Name View Source Status
0001564590-15-001392-index-headers.html Edgar Link pending
0001564590-15-001392-index.html Edgar Link pending
0001564590-15-001392.txt Edgar Link pending
0001564590-15-001392-xbrl.zip Edgar Link pending
biol-10k_20141231.htm Edgar Link pending
biol-20141231.xml Edgar Link completed
biol-20141231.xsd Edgar Link pending
biol-20141231_cal.xml Edgar Link unprocessable
biol-20141231_def.xml Edgar Link unprocessable
biol-20141231_lab.xml Edgar Link unprocessable
biol-20141231_pre.xml Edgar Link unprocessable
biol-ex1025_20141231872.htm Edgar Link pending
biol-ex211_20141231419.htm Edgar Link pending
biol-ex231_20141231871.htm Edgar Link pending
biol-ex311_20141231427.htm Edgar Link pending
biol-ex321_20141231428.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201503062019559673347.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending